[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Recursion Pharmaceuticals Inc Cl A (RXRX)

Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,775,182
  • Shares Outstanding, K 529,905
  • Annual Sales, $ 74,680 K
  • Annual Income, $ -644,760 K
  • EBIT $ -544 M
  • EBITDA $ -460 M
  • 60-Month Beta 1.03
  • Price/Sales 23.34
  • Price/Cash Flow N/A
  • Price/Book 1.91

Options Overview Details

View History
  • Implied Volatility 67.56% (+5.70%)
  • Historical Volatility 56.88%
  • IV Percentile 1%
  • IV Rank 3.55%
  • IV High 222.65% on 01/14/26
  • IV Low 61.86% on 08/11/26
  • Expected Move (DTE 2) 0.22 (6.74%)
  • Put/Call Vol Ratio 0.15
  • Today's Volume 937
  • Volume Avg (30-Day) 9,643
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 359,585
  • Open Int (30-Day) 349,166
  • Expected Range 3.06 to 3.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.22
  • Number of Estimates 4
  • High Estimate $-0.20
  • Low Estimate $-0.24
  • Prior Year $-0.36
  • Growth Rate Est. (year over year) +38.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.84 +15.67%
on 07/20/26
3.54 -7.20%
on 07/13/26
-0.27 (-7.72%)
since 07/10/26
3-Month
2.77 +18.59%
on 05/19/26
4.09 -19.68%
on 07/06/26
+0.13 (+4.29%)
since 05/12/26
52-Week
2.77 +18.59%
on 05/19/26
7.18 -54.25%
on 10/20/25
-2.12 (-39.28%)
since 08/12/25

Most Recent Stories

More News
Recursion Pharmaceuticals: Q2 Earnings Snapshot

Recursion Pharmaceuticals: Q2 Earnings Snapshot

RXRX : 3.30 (-1.49%)
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated targets...

RXRX : 3.30 (-1.49%)
Recursion's AI Drug Discovery Timeline Gets Its Quarterly Reality Check

Barchart Research What to Expect from RXRX Earnings RXRX Generated August 4, 2026 Current Price $3.31 EPS Estimate $$-0.23 Consensus Rating Moderate Buy Average Move 5.39% Recursion's AI Drug Discovery...

RXRX : 3.30 (-1.49%)
Recursion to Participate in Upcoming Investor Conferences

Salt Lake City, UT, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation...

RXRX : 3.30 (-1.49%)
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Salt Lake City, UT, July 31, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on July 27, 2026,...

RXRX : 3.30 (-1.49%)
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th

Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) -- Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) – Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically...

RXRX : 3.30 (-1.49%)
1 of the Most Interesting AI Stocks in the Market Isn’t a Tech Company

Recursion Pharmaceuticals is trying to prove that AI’s next big winner can also come from biotech, and not just from the tech sector.

RXRX : 3.30 (-1.49%)
RHHBY : 56.0600 (-0.99%)
SNY : 43.46 (-0.23%)
Recursion to Participate in Upcoming Investor Conferences

Salt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation...

RXRX : 3.30 (-1.49%)
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Salt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the...

RXRX : 3.30 (-1.49%)
A Deep Dive Into NVIDIA’s Latest Portfolio Moves

NVIDIA's latest 13F filing does not tell the story it seems to at first glance. The apparent divergence in its CoreWeave and Nebius holdings is a prime example.

NVDA : 223.84 (+2.91%)
CRWV : 107.72 (+19.26%)
GENB : 14.64 (+2.59%)
INTC : 100.87 (+3.23%)
SNPS : 412.85 (+0.47%)
COHR : 352.80 (+7.37%)
NBIS : 238.91 (+23.64%)
RXRX : 3.30 (-1.49%)
NOK : 10.35 (+9.64%)
LITE : 927.82 (+13.07%)
MRVL : 224.00 (+5.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering. Recursion Pharmaceuticals Inc. is based in SALT LAKE CITY.

See More

Key Turning Points

3rd Resistance Point 3.57
2nd Resistance Point 3.50
1st Resistance Point 3.42
Last Price 3.30
1st Support Level 3.27
2nd Support Level 3.20
3rd Support Level 3.12

See More

52-Week High 7.18
Fibonacci 61.8% 5.50
Fibonacci 50% 4.97
Fibonacci 38.2% 4.45
Last Price 3.30
52-Week Low 2.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.